<?xml version = '1.0' encoding = 'UTF-8'?>
<?xml-stylesheet href="/rss/styledrssBMC.css" type="text/css"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns="http://purl.org/rss/1.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:extra="http://www.biomedcentral.com/xml/schemas/extra/" xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/" xmlns:cc="http://web.resource.org/cc/">
	<channel rdf:about="http://www.biomedcentral.com/rss">
		<extra:info rdf:parseType="Literal">
			<html:div xmlns:html="http://www.w3.org/1999/xhtml" style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif">
				<html:span style="font-weight:bold">This is an RSS newsfeed from BioMed Central</html:span>
				<html:br/>
				<html:span style="font-size: 12px;">It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit <html:br/><html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">http://www.biomedcentral.com/info/about/rss/</html:a><html:br/>
				</html:span>
			</html:div>
		</extra:info>
		<title>BMC Pulmonary Medicine - Most viewed articles</title>
		<link>http://www.biomedcentral.com/bmcpulmmed/mostviewed/</link>
		<description>Most viewed articles in last 30 days from BMC Pulmonary Medicine (ISSN 1471-2466) published by 
				
				BioMed Central
		</description>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
         <items>
            <rdf:Seq>
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2466/8/12"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2466/8/17"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2466/8/14"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2466/8/16"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2466/8/13"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2466/8/15"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2466/8/9"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2466/7/8"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2466/8/10"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2466/7/2"/>			    
            
            </rdf:Seq>
        </items>
    </channel>
    
		<item rdf:about="http://www.biomedcentral.com/1471-2466/8/12">
            
            <title>Hospital acquired pneumonia with high-risk bacteria is associated with increased pulmonary matrix metalloproteinase activity</title>
			<description>Background:
Neutrophil products like matrix metalloproteinases (MMP), involved in bacterial defence mechanisms, possibly induce lung damage and are elevated locally during hospital- acquired pneumonia (HAP). In HAP the virulence of bacterial species is known to be different. The aim of this study was to investigate the influence of high-risk bacteria like S. aureus and pseudomonas species on pulmonary MMPconcentration in human pneumonia.
Methods:
In 37 patients with HAP and 16 controls, MMP-8, MMP-9 and tissue inhibitors of MMP (TIMP) were analysed by ELISA and MMP-9 activity using zymography in bronchoalveolar lavage (BAL).
Results:
MMP-9 activity in mini-BAL was increased in HAP patients versus controls (149 &#177; 41 vs. 34 &#177; 11, p &lt; 0.0001). In subgroup analysis, the highest MMP concentrations and activity were seen in patients with high-risk bacteria: patients with high-risk bacteria MMP-9 1168 &#177; 266 vs. patients with low-risk bacteria 224 &#177; 119 ng/ml p &lt; 0.0001, MMP-9 gelatinolytic activity 325 &#177; 106 vs. 67 &#177; 14, p &lt; 0.0002. In addition, the MMP-8 and MMP-9 concentration was associated with the state of ventilation and systemic inflammatory marker like CRP.
Conclusion:
Pulmonary MMP concentrations and MMP activity are elevated in patients with HAP. This effect is most pronounced in patients with high-risk bacteria. Artificial ventilation may play an additional role in protease activation.</description>
			<link>http://www.biomedcentral.com/1471-2466/8/12</link>		
			<dc:creator>Bernhard Schaaf, Cornelia Liebau, Volkhard Kurowski, Daniel Droemann and Klaus Dalhoff</dc:creator>
			<dc:source>BMC Pulmonary Medicine 2008, 8:12</dc:source>
			<dc:subject>Number of accesses: 362</dc:subject>
			<dc:date>2008-08-12</dc:date>
			<dc:identifier>doi:10.1186/1471-2466-8-12</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pulmonary Medicine</prism:publicationName>
					
			
							
					<prism:issn>1471-2466</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>12</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-08-12</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2466/8/17">
            
            <title>Effect of roflumilast on inflammatory cells in the lungs of cigarette smoke-exposed mice</title>
			<description>Background:
In a previous study we have reported that roflumilast, a phosphodiesterase 4 inhibitor, given orally at 5 mg/kg to mice prevented the development of emphysema in a chronic model of cigarette smoke exposure, while at 1 mg/kg was ineffective. Here we investigated the effects of roflumilast on the volume density (VV ) of the inflammatory cells present in the lungs after chronic cigarette smoke exposure.
Methods:
Slides were obtained from blocks of the previous study and VV was assessed immunohistochemically and by point counting using a grid with 48 points, a 20x objective and a computer screen for a final magnification of 580x. Neutrophils were marked with myeloperoxidase antibody, macrophages with Mac-3, dendritic cells with fascin, B-lymphocytes with B220, CD4+ T-cells with CD4+ antibody, and CD8+T-cells with CD8-alpha. The significance of the differences was calculated using one-way analysis of variance.
Results:
Chronic smoke exposure increased neutrophil VV by 97%, macrophage by 107%, dendritic cell by 217%, B-lymphocyte by 436%, CD4+ by 524%, and CD8+ by 417%. The higher dose of roflumilast prevented the increase in neutrophil VV by 78%, macrophage by 82%, dendritic cell by 48%, B-lymphocyte by 100%, CD4+ by 98% and CD8+ VV by 88%. The lower dose of roflumilast did not prevent the increase in neutrophil, macrophage and B-cell VV but prevented dendritic cells by 42%, CD4+ by 55%, and CD8+ by 91%.
Conclusions:
These results indicate ((i) chronic exposure to cigarette smoke in mice results in a significant recruitment into the lung of inflammatory cells of both the innate and adaptive immune system; (ii) roflumilast at the higher dose exerts a protective effect against the recruitment of all these cells and at the lower dose against the recruitment of dendritic cells and T-lymphocytes; (iii) these findings underline the role of innate immunity in the development of pulmonary emphysema and (iiii) support  previous results indicating that the inflammatory cells of the adaptive immune system do not play a central role in the development of cigarette smoke induced emphysema in mice. </description>
			<link>http://www.biomedcentral.com/1471-2466/8/17</link>		
			<dc:creator>Piero A Martorana, Benedetta Lunghi, Monica Lucattelli, Giovanna De Cunto, Rolf Beume and Giuseppe Lungarella</dc:creator>
			<dc:source>BMC Pulmonary Medicine 2008, 8:17</dc:source>
			<dc:subject>Number of accesses: 346</dc:subject>
			<dc:date>2008-08-28</dc:date>
			<dc:identifier>doi:10.1186/1471-2466-8-17</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pulmonary Medicine</prism:publicationName>
					
			
							
					<prism:issn>1471-2466</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>17</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-08-28</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2466/8/14">
            
            <title>Discriminative and predictive properties of disease-specific and generic health status indexes in elderly COPD patients</title>
			<description>Background:
The association between bronchial obstruction severity and mortality in Chronic Obstructive Pulmonary Disease (COPD) is well established, but it is unknown whether disease-specific health status measures and multidimensional assessment (MDA) have comparable prognostic value.
Methods:
We analyzed data coming from the Salute Respiratoria nell'Anziano (Respiratory Health in the Elderly &#8211; SaRA) study, enrolling elderly people attending outpatient clinics for respiratory and non-respiratory problems. From this population we selected 449 patients with bronchial obstruction (77.3% men, mean age 73.1). We classified patients' health status using tertiles of the Saint George Respiratory Questionnaire (SGRQ) and a MDA including functional (the 6' walking test, WT), cognitive (Mini-Mental State Examination, MMSE) and affective status (Geriatric Depression Scale, GDS). The agreement of the classification methods was calculated using the kappa statistic, and survival associated with group membership was evaluated using survival analysis.
Results:
Pulmonary function, expressed by the FEV1, worsened with increasing SGRQ or MDA scores. Cognitive function was not associated with the SGRQ, while physical performance and mood status were impaired only in the highest tertile of SGRQ. A poor agreement was found between the two classification systems tested (k = 0.194). Compared to people in the first tertile of SGRQ score, those in the second tertile had a sex-adjusted HR of 1.22 (0.75 &#8211; 1.98) and those in the third tertile of 2.90 (1.92 &#8211; 4.40). The corresponding figures of the MDA were 1.49 (95% CI 1.02 &#8211; 2.18) and 2.01 (95% CI: 1.31 &#8211; 3.08). After adjustment for severity of obstruction, only a SGRQ in the upper tertile was associated with mortality (HR: 1.86; 95% CI: 1.14 &#8211; 3.02).
Conclusion:
In elderly outpatients with mild-moderate COPD, a disease-specific health status index seems to be a better predictor of death compared to a MDA.</description>
			<link>http://www.biomedcentral.com/1471-2466/8/14</link>		
			<dc:creator>Maria E Conte, Claudio Pedone, Francesco Forastiere, Vincenzo Bellia and Raffaele Antonelli-Incalzi</dc:creator>
			<dc:source>BMC Pulmonary Medicine 2008, 8:14</dc:source>
			<dc:subject>Number of accesses: 341</dc:subject>
			<dc:date>2008-08-13</dc:date>
			<dc:identifier>doi:10.1186/1471-2466-8-14</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pulmonary Medicine</prism:publicationName>
					
			
							
					<prism:issn>1471-2466</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>14</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-08-13</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2466/8/16">
            
            <title>Hyponatremia and hospital outcomes among patients with pneumonia: a retrospective cohort study</title>
			<description>Background:
Community-acquired (CAP) and nosocomial pneumonias contribute substantially to morbidity and hospital resource utilization. Hyponatremia, occurring in >1/4 of patients with CAP, is associated with greater disease severity and worsened outcomes.
Methods:
To explore how hyponatremia is associated with outcomes in hospitalized patients with pneumonia, we analyzed a large administrative database with laboratory component from January 2004 to December 2005. Hyponatremia was defined as at least two [Na+] &lt; 135 mEq/L within 24 hours of admission value.
Results:
Of 7,965 patients with pneumonia, 649 (8.1%) with hyponatremia were older (72.4 &#177; 15.7 vs. 68.0 &#177; 22.0, p &lt; 0.01), had a higher mean Deyo-Charlson Comorbidity Index Score (1.7 &#177; 1.7 vs. 1.6 &#177; 1.6, p = 0.02), and higher rates of ICU (10.0% vs. 6.3%, p &lt; 0.001) and MV (3.9% vs. 2.3%, p = 0.01) in the first 48 hours of hospitalization than patients with normal sodium. Hyponatremia was associated with an increased ICU (6.3 &#177; 5.6 vs. 5.3 &#177; 5.1 days, p = 0.07) and hospital lengths of stay (LOS, 7.6 &#177; 5.3 vs. 7.0 &#177; 5.2 days, p &lt; 0.001) and a trend toward increased hospital mortality (5.4% vs. 4.0%, p = 0.1). After adjusting for confounders, hyponatremia was associated with an increased risk of ICU (OR 1.58, 95% CI 1.20&#8211;2.08), MV (OR 1.75 95% CI 1.13&#8211;2.69), and hospital death (OR 1.3, 95% CI 0.90&#8211;1.87) and with increases of 0.8 day to ICU and 0.3 day to hospital LOS, and over $1,300 to total hospital costs.
Conclusion:
Hyponatremia is common among hospitalized patients with pneumonia and is associated with worsened clinical and economic outcomes. Studies in this large population are needed to explore whether prompt correction of [Na+] may impact these outcomes.</description>
			<link>http://www.biomedcentral.com/1471-2466/8/16</link>		
			<dc:creator>Marya D Zilberberg, Alex Exuzides, James Spalding, Aimee Foreman, Alison Graves Jones, Chris Colby and Andrew F Shorr</dc:creator>
			<dc:source>BMC Pulmonary Medicine 2008, 8:16</dc:source>
			<dc:subject>Number of accesses: 338</dc:subject>
			<dc:date>2008-08-18</dc:date>
			<dc:identifier>doi:10.1186/1471-2466-8-16</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pulmonary Medicine</prism:publicationName>
					
			
							
					<prism:issn>1471-2466</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>16</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-08-18</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2466/8/13">
            
            <title>Human eosinophil adhesion and degranulation stimulated with eotaxin and RANTES in vitro: Lack of interaction with nitric oxide</title>
			<description>Background:
Airway eosinophilia is considered a central event in the pathogenesis of asthma. The toxic components of eosinophils are thought to be important in inducing bronchial mucosal injury and dysfunction. Previous studies have suggested an interaction between nitric oxide (NO) and chemokines in modulating eosinophil functions, but this is still conflicting. In the present study, we have carried out functional assays (adhesion and degranulation) and flow cytometry analysis of adhesion molecules (VLA-4 and Mac-1 expression) to evaluate the interactions between NO and CC-chemokines (eotaxin and RANTES) in human eosinophils.
Methods:
Eosinophils were purified using a percoll gradient followed by immunomagnetic cell separator. Cell adhesion and degranulation were evaluated by measuring eosinophil peroxidase (EPO) activity, whereas expression of Mac-1 and VLA-4 was detected using flow cytometry.
Results:
At 4 h incubation, both eotaxin (100 ng/ml) and RANTES (1000 ng/ml) increased by 133% and 131% eosinophil adhesion, respectively. L-NAME alone (but not D-NAME) also increased the eosinophil adhesion, but the co-incubation of L-NAME with eotaxin or RANTES did not further affect the increased adhesion seen with chemokines alone. In addition, L-NAME alone (but not D-NAME) caused a significant cell degranulation, but it did not affect the CC-chemokine-induced cell degranulation. Incubation of eosinophils with eotaxin or RANTES, in absence or presence of L-NAME, did not affect the expression of VLA-4 and Mac-1 on eosinophil surface. Eotaxin and RANTES (100 ng/ml each) also failed to elevate the cyclic GMP levels above baseline in human eosinophils.
Conclusion:
Eotaxin and RANTES increase the eosinophil adhesion to fibronectin-coated plates and promote cell degranulation by NO-independent mechanisms. The failure of CC-chemokines to affect VLA-4 and Mac-1 expression suggests that changes in integrin function (avidity or affinity) are rather involved in the enhanced adhesion.</description>
			<link>http://www.biomedcentral.com/1471-2466/8/13</link>		
			<dc:creator>Let&#237;cia Lintomen, Gilberto Franchi, Alexandre Nowill, Antonio Condino-Neto, Gilberto de Nucci, Angelina Zanesco and Edson Antunes</dc:creator>
			<dc:source>BMC Pulmonary Medicine 2008, 8:13</dc:source>
			<dc:subject>Number of accesses: 277</dc:subject>
			<dc:date>2008-08-12</dc:date>
			<dc:identifier>doi:10.1186/1471-2466-8-13</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pulmonary Medicine</prism:publicationName>
					
			
							
					<prism:issn>1471-2466</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>13</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-08-12</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2466/8/15">
            
            <title>Angiotensin-converting enzyme genotype and late respiratory complications of mustard gas exposure</title>
			<description>Background:
Exposure to mustard gas frequently results in long-term respiratory complications. However the factors which drive the development and progression of these complications remain unclear. The Renin Angiotensin System (RAS) has been implicated in lung inflammatory and fibrotic responses. Genetic variation within the gene coding for the Angiotensin Converting Enzyme (ACE), specifically the Insertion/Deletion polymorphism (I/D), is associated with variable levels of ACE and with the severity of several acute and chronic respiratory diseases. We hypothesized that the ACE genotype might influence the severity of late respiratory complications of mustard gas exposure.
Methods:
208 Kurdish patients who had suffered high exposure to mustard gas, as defined by cutaneous lesions at initial assessment, in Sardasht, Iran on June 29 1987, underwent clinical examination, spirometric evaluation and ACE Insertion/Deletion genotyping in September 2005.
Results:
ACE genotype was determined in 207 subjects. As a continuous variable, FEV1 % predicted tended to be higher in association with the D allele 68.03 &#177; 20.5%, 69.4 &#177; 21.4% and 74.8 &#177; 20.1% for II, ID and DD genotypes respectively. Median FEV1 % predicted was 73 and this was taken as a cut off between groups defined as having better or worse lung function. The ACE DD genotype was overrepresented in the better spirometry group (Chi2 4.9 p = 0.03). Increasing age at the time of exposure was associated with reduced FEV1 %predicted (p = 0.001), whereas gender was not (p = 0.43).
Conclusion:
The ACE D allele is associated with higher FEV1 % predicted when assessed 18 years after high exposure to mustard gas.</description>
			<link>http://www.biomedcentral.com/1471-2466/8/15</link>		
			<dc:creator>Ali Reza Hosseini-khalili, Julian Thompson, Anthony Kehoe, Nicholas S Hopkinson, A Khoshbaten, Mohammad Reza Soroush, Steve E Humphries, Hugh Montgomery and Mostafa Ghanei</dc:creator>
			<dc:source>BMC Pulmonary Medicine 2008, 8:15</dc:source>
			<dc:subject>Number of accesses: 264</dc:subject>
			<dc:date>2008-08-14</dc:date>
			<dc:identifier>doi:10.1186/1471-2466-8-15</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pulmonary Medicine</prism:publicationName>
					
			
							
					<prism:issn>1471-2466</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>15</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-08-14</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2466/8/9">
            
            <title>Hypertonic saline reduces inflammation and enhances the resolution of oleic acid induced acute lung injury</title>
			<description>Background:
Hypertonic saline (HTS) reduces the severity of lung injury in ischemia-reperfusion, endotoxin-induced and ventilation-induced lung injury. However, the potential for HTS to modulate the resolution of lung injury is not known. We investigated the potential for hypertonic saline to modulate the evolution and resolution of oleic acid induced lung injury.
Methods:
Adult male Sprague Dawley rats were used in all experiments. Series 1 examined the potential for HTS to reduce the severity of evolving oleic acid (OA) induced acute lung injury. Following intravenous OA administration, animals were randomized to receive isotonic (Control, n = 12) or hypertonic saline (HTS, n = 12), and the extent of lung injury assessed after 6 hours. Series 2 examined the potential for HTS to enhance the resolution of oleic acid (OA) induced acute lung injury. Following intravenous OA administration, animals were randomized to receive isotonic (Control, n = 6) or hypertonic saline (HTS, n = 6), and the extent of lung injury assessed after 6 hours.
Results:
In Series I, HTS significantly reduced bronchoalveolar lavage (BAL) neutrophil count compared to Control [61.5 &#177; 9.08 versus 102.6 &#177; 11.89 &#215; 103 cells.ml-1]. However, there were no between group differences with regard to: A-a O2 gradient [11.9 &#177; 0.5 vs. 12.0 &#177; 0.5 KPa]; arterial PO2; static lung compliance, or histologic injury. In contrast, in Series 2, hypertonic saline significantly reduced histologic injury and reduced BAL neutrophil count [24.5 &#177; 5.9 versus 46.8 &#177; 4.4 &#215; 103 cells.ml-1], and interleukin-6 levels [681.9 &#177; 190.4 versus 1365.7 &#177; 246.8 pg.ml-1].
Conclusion:
These findings demonstrate, for the first time, the potential for HTS to reduce pulmonary inflammation and enhance the resolution of oleic acid induced lung injury.</description>
			<link>http://www.biomedcentral.com/1471-2466/8/9</link>		
			<dc:creator>Muiris T Kennedy, Brendan D Higgins, Joseph F Costello, William A Curtin and John G Laffey</dc:creator>
			<dc:source>BMC Pulmonary Medicine 2008, 8:9</dc:source>
			<dc:subject>Number of accesses: 233</dc:subject>
			<dc:date>2008-07-08</dc:date>
			<dc:identifier>doi:10.1186/1471-2466-8-9</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pulmonary Medicine</prism:publicationName>
					
			
							
					<prism:issn>1471-2466</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>9</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-07-08</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2466/7/8">
            
            <title>Can asthma control be improved by understanding the patient's perspective?</title>
			<description>Background:
Clinical trials show that asthma can be controlled in the majority of patients, but poorly controlled asthma still imposes a considerable burden. The level of asthma control achieved reflects the behaviour of both healthcare professionals and patients. A key challenge for healthcare professionals is to help patients to engage in self-management behaviours with optimal adherence to appropriate treatment. These issues are particularly relevant in primary care, where most asthma is managed. An international panel of experts invited by the International Primary Care Respiratory Group considered the evidence and discussed the implications for primary care practice.DiscussionCauses of poor controlClinical factors such as exposure to triggers and concomitant rhinitis are important but so are patient behavioural factors. Behaviours such as smoking and nonadherence may reduce the efficacy of treatment and patients' perceptions influence these behaviours. Perceptual barriers to adherence include doubting the need for treatment when symptoms are absent and concerns about potential adverse effects. Under-treatment may also be related to patients' underestimation of the significance of symptoms, and lack of awareness of achievable control.ImplicationsThree key implications for healthcare professionals emerged from the debate. First, the need for simple tools to assess asthma control. Two approaches considered were the monitoring of biometric markers of control and questionnaires to record patient-reported outcomes. Second, to understand the reasons for poor control for individual patients, identifying both clinical (e.g. rhinitis) and behavioural factors (e.g. smoking and nonadherence to treatment). Third was the need to incorporate, within asthma review, an assessment of patient perspectives including their goals and aspirations and to elicit their beliefs and concerns about asthma and its treatment. This can be used as a basis for agreement between the healthcare professional and patient on a predefined target regarding asthma control and a treatment plan to achieve this.SummaryOptimum review of asthma is essential to improve control. A key priority is the development of simple and effective tools for identifying poor control for individual patients coupled with a tailored approach to treatment to enable patients to set and achieve realistic goals for asthma control.</description>
			<link>http://www.biomedcentral.com/1471-2466/7/8</link>		
			<dc:creator>Rob Horne, David Price, Jen Cleland, Rui Costa, Donna Covey, Kevin Gruffydd-Jones, John Haughney, Svein Hoegh Henrichsen, Alan Kaplan, Arnulf Langhammer, Anders &#216;strem, Mike Thomas, Thys van der Molen, J Christian Virchow and Si&#226;n Williams</dc:creator>
			<dc:source>BMC Pulmonary Medicine 2007, 7:8</dc:source>
			<dc:subject>Number of accesses: 208</dc:subject>
			<dc:date>2007-05-22</dc:date>
			<dc:identifier>doi:10.1186/1471-2466-7-8</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pulmonary Medicine</prism:publicationName>
					
			
							
					<prism:issn>1471-2466</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>8</prism:startingPage>
					
			
							
					<prism:publicationDate>2007-05-22</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2466/8/10">
            
            <title>Surfactant replacement and open lung concept &#8211; Comparison of two treatment strategies in an experimental model of neonatal ARDS</title>
			<description>Background:
Several concepts of treatment in neonatal ARDS have been proposed in the last years. The present study compared the effects of open lung concept positive pressure ventilation (PPVOLC) with a conventional ventilation strategy combined with administration of two different surfactant preparations on lung function and surfactant homoeostasis.
Methods:
After repeated whole-lung saline lavage, 16 newborn piglets were assigned to either PPVOLC (n = 5) or surfactant treatment under conventional PPV using a natural bovine (n = 5) or a monomeric protein B based surfactant (n = 6).
Results:
Comprehensive monitoring showed each treatment strategy to improve gas exchange and lung function, although the effect on PaO2 and pulmonary compliance declined over the study period in the surfactant groups. The overall improvement of the ventilation efficiency index (VEI) was significantly greater in the PPVOLC group. Phospholipid and protein analyses of the bronchoalveolar lavage fluid showed significant alterations to surfactant homoeostasis in the PPVOLC group, whereas IL-10 and SP-C mRNA expression was tendentially increased in the surfactant groups.
Conclusion:
The different treatment strategies applied could be shown to improve gas exchange and lung function in neonatal ARDS. To which extent differences in maintenance of lung function and surfactant homeostasis may lead to long-term consequences needs to be studied further.</description>
			<link>http://www.biomedcentral.com/1471-2466/8/10</link>		
			<dc:creator>Anne Hilgendorff, Ece Aslan, Thomas Schaible, Ludwig Gortner, Thorsten Baehner, Michael Ebsen, Jochen Kreuder, Clemens Ruppert, Andreas Guenther and Irwin Reiss</dc:creator>
			<dc:source>BMC Pulmonary Medicine 2008, 8:10</dc:source>
			<dc:subject>Number of accesses: 191</dc:subject>
			<dc:date>2008-07-14</dc:date>
			<dc:identifier>doi:10.1186/1471-2466-8-10</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pulmonary Medicine</prism:publicationName>
					
			
							
					<prism:issn>1471-2466</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>10</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-07-14</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2466/7/2">
            
            <title>Aerosolized amikacin for treatment of pulmonary Mycobacterium avium infections: an observational case series</title>
			<description>Background:
Current systemic therapy for nontuberculous mycobacterial pulmonary infection is limited by poor clinical response rates, drug toxicities and side effects. The addition of aerosolized amikacin to standard oral therapy for nontuberculous mycobacterial pulmonary infection may improve treatment efficacy without producing systemic toxicity. This study was undertaken to assess the safety, tolerability and preliminary clinical benefits of the addition of aerosolized amikacin to a standard macrolide-based oral treatment regimen.Case PresentationsSix HIV-negative patients with Mycobacterium avium intracellulare pulmonary infections who had failed standard therapy were administered aerosolized amikacin at 15 mg/kg daily in addition to standard multi-drug macrolide-based oral therapy. Patients were monitored clinically and serial sputum cultures were obtained to assess response to therapy. Symptomatic improvement with radiographic stabilization and eradication of mycobacterium from sputum were considered markers of success.Of the six patients treated with daily aerosolized amikacin, five responded to therapy. All of the responders achieved symptomatic improvement and four were sputum culture negative after 6 months of therapy. Two patients became re-infected with Mycobacterium avium intracellulare after 7 and 21 months of treatment. One of the responders who was initially diagnosed with Mycobacterium avium intracellulare became sputum culture positive for Mycobacterium chelonae resistant to amikacin after being on intermittent therapy for 4 years. One patient had progressive respiratory failure and died despite additional therapy. There was no evidence of nephrotoxicity or ototoxicity associated with therapy.
Conclusion:
Aerosolized delivery of amikacin is a promising adjunct to standard therapy for pulmonary nontuberculous mycobacterial infections. Larger prospective trials are needed to define its optimal role in therapy of this disease.</description>
			<link>http://www.biomedcentral.com/1471-2466/7/2</link>		
			<dc:creator>Kala K Davis, Peter N Kao, Susan S Jacobs and Stephen J Ruoss</dc:creator>
			<dc:source>BMC Pulmonary Medicine 2007, 7:2</dc:source>
			<dc:subject>Number of accesses: 187</dc:subject>
			<dc:date>2007-02-23</dc:date>
			<dc:identifier>doi:10.1186/1471-2466-7-2</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pulmonary Medicine</prism:publicationName>
					
			
							
					<prism:issn>1471-2466</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>2</prism:startingPage>
					
			
							
					<prism:publicationDate>2007-02-23</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
		
	<cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
         <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks"/>
	</cc:License>
</rdf:RDF>
